Rgenta Therapeutics
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Domain
rgentatx.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$8.0M
Founded
2017
Tech Stack (14 technologies)
Frequently Asked Questions
What technologies does Rgenta Therapeutics use?+
Rgenta Therapeutics uses 14 technologies including jQuery Migrate, HSTS, Nginx.
What industry is Rgenta Therapeutics in?+
Rgenta Therapeutics operates in the Biotechnology industry.
Where is Rgenta Therapeutics based?+
Rgenta Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026